Open Access
npj Vaccines, volume 7, issue 1, publication number 145
Anti-Ad26 humoral immunity does not compromise SARS-COV-2 neutralizing antibody responses following Gam-COVID-Vac booster vaccination
Byazrova M G
1, 2, 3
,
Astakhova Ekaterina A
1, 2
,
Minnegalieva Aygul R
4
,
Sukhova Maria M
1, 2
,
Mikhailov Artem A
1, 2
,
Prilipov Alexey G
1, 5
,
Gorchakov Andrey A
6
,
Filatov A V
1, 2
4
Institute of Science and Technology Austria (IST Austria), Klosterneuburg, Austria
|
Publication type: Journal Article
Publication date: 2022-11-15
PubMed ID:
36379998
Pharmacology
Infectious Diseases
Pharmacology (medical)
Immunology
Abstract
Replication-incompetent adenoviral vectors have been extensively used as a platform for vaccine design, with at least four anti-COVID-19 vaccines authorized to date. These vaccines elicit neutralizing antibody responses directed against SARS-CoV-2 Spike protein and confer significant level of protection against SARS-CoV-2 infection. Immunization with adenovirus-vectored vaccines is known to be accompanied by the production of anti-vector antibodies, which may translate into reduced efficacy of booster or repeated rounds of revaccination. Here, we used blood samples from patients who received an adenovirus-based Gam-COVID-Vac vaccine to address the question of whether anti-vector antibodies may influence the magnitude of SARS-CoV-2-specific humoral response after booster vaccination. We observed that rAd26-based prime vaccination with Gam-COVID-Vac induced the development of Ad26-neutralizing antibodies, which persisted in circulation for at least 9 months. Our analysis further indicates that high pre-boost Ad26 neutralizing antibody titers do not appear to affect the humoral immunogenicity of the Gam-COVID-Vac boost. The titers of anti-SARS-CoV-2 RBD IgGs and antibodies, which neutralized both the wild type and the circulating variants of concern of SARS-CoV-2 such as Delta and Omicron, were independent of the pre-boost levels of Ad26-neutralizing antibodies. Thus, our results support the development of repeated immunization schedule with adenovirus-based COVID-19 vaccines.
Citations by journals
|
1
|
|
|
Viruses
|
Viruses
1 publication, 20%
|
|
Frontiers in Immunology
|
Frontiers in Immunology
1 publication, 20%
|
|
Vaccines
|
Vaccines
1 publication, 20%
|
|
Vaccine
|
Vaccine
1 publication, 20%
|
|
Virology
|
Virology
1 publication, 20%
|
|
1
|
Citations by publishers
|
1
2
|
|
|
Multidisciplinary Digital Publishing Institute (MDPI)
|
Multidisciplinary Digital Publishing Institute (MDPI)
2 publications, 40%
|
|
Elsevier
|
Elsevier
2 publications, 40%
|
|
Frontiers Media S.A.
|
Frontiers Media S.A.
1 publication, 20%
|
|
1
2
|
- We do not take into account publications that without a DOI.
- Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
- Statistics recalculated weekly.
{"yearsCitations":{"type":"bar","data":{"show":true,"labels":[2023,2024],"ids":[0,0],"codes":[0,0],"imageUrls":["",""],"datasets":[{"label":"Citations number","data":[4,1],"backgroundColor":["#3B82F6","#3B82F6"],"percentage":["80","20"],"barThickness":null}]},"options":{"indexAxis":"x","maintainAspectRatio":true,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"}},"x":{"ticks":{"stepSize":1,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"}}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Citations per year","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}},"journals":{"type":"bar","data":{"show":true,"labels":["Viruses","Frontiers in Immunology","Vaccines","Vaccine","Virology"],"ids":[2455,1699,24868,8548,2128],"codes":[0,0,0,0,0],"imageUrls":["\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/4QWA67eqfcfyOiA8Wk7YnqroHFqQbTsmDJUYTCTg_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp"],"datasets":[{"label":"","data":[1,1,1,1,1],"backgroundColor":["#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6"],"percentage":[20,20,20,20,20],"barThickness":13}]},"options":{"indexAxis":"y","maintainAspectRatio":false,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"}},"x":{"ticks":{"stepSize":null,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"}}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Journals","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}},"publishers":{"type":"bar","data":{"show":true,"labels":["Multidisciplinary Digital Publishing Institute (MDPI)","Elsevier","Frontiers Media S.A."],"ids":[202,17,208],"codes":[0,0,0],"imageUrls":["\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/4QWA67eqfcfyOiA8Wk7YnqroHFqQbTsmDJUYTCTg_medium.webp"],"datasets":[{"label":"","data":[2,2,1],"backgroundColor":["#3B82F6","#3B82F6","#3B82F6"],"percentage":[40,40,20],"barThickness":13}]},"options":{"indexAxis":"y","maintainAspectRatio":false,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"}},"x":{"ticks":{"stepSize":null,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"}}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Publishers","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}}}
Metrics
Cite this
GOST |
RIS |
BibTex
Cite this
GOST
Copy
Byazrova M. G. et al. Anti-Ad26 humoral immunity does not compromise SARS-COV-2 neutralizing antibody responses following Gam-COVID-Vac booster vaccination // npj Vaccines. 2022. Vol. 7. No. 1. 145
GOST all authors (up to 50)
Copy
Byazrova M. G., Astakhova E. A., Minnegalieva A. R., Sukhova M. M., Mikhailov A. A., Prilipov A. G., Gorchakov A. A., Filatov A. V. Anti-Ad26 humoral immunity does not compromise SARS-COV-2 neutralizing antibody responses following Gam-COVID-Vac booster vaccination // npj Vaccines. 2022. Vol. 7. No. 1. 145
Cite this
RIS
Copy
TY - JOUR
DO - 10.1038/s41541-022-00566-x
UR - https://doi.org/10.1038%2Fs41541-022-00566-x
TI - Anti-Ad26 humoral immunity does not compromise SARS-COV-2 neutralizing antibody responses following Gam-COVID-Vac booster vaccination
T2 - npj Vaccines
AU - Byazrova, M G
AU - Astakhova, Ekaterina A
AU - Minnegalieva, Aygul R
AU - Sukhova, Maria M
AU - Mikhailov, Artem A
AU - Prilipov, Alexey G
AU - Gorchakov, Andrey A
AU - Filatov, A V
PY - 2022
DA - 2022/11/15 00:00:00
PB - Springer Nature
IS - 1
VL - 7
PMID - 36379998
SN - 2059-0105
ER -
Cite this
BibTex
Copy
@article{2022_Byazrova,
author = {M G Byazrova and Ekaterina A Astakhova and Aygul R Minnegalieva and Maria M Sukhova and Artem A Mikhailov and Alexey G Prilipov and Andrey A Gorchakov and A V Filatov},
title = {Anti-Ad26 humoral immunity does not compromise SARS-COV-2 neutralizing antibody responses following Gam-COVID-Vac booster vaccination},
journal = {npj Vaccines},
year = {2022},
volume = {7},
publisher = {Springer Nature},
month = {nov},
url = {https://doi.org/10.1038%2Fs41541-022-00566-x},
number = {1},
doi = {10.1038/s41541-022-00566-x}
}